Skin Flap Visible Light Spectroscopy (VLS) Oximetry for Monitoring Free-Flap Ischemia During Breast Reconstruction and Recovery
The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2011 by Spectros Corporation.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Spectros Corporation
Collaborators:
Mills-Peninsula Medical Center
Stanford University
Information provided by:
Spectros Corporation
ClinicalTrials.gov Identifier:
NCT01173133
First received: July 28, 2010
Last updated: January 30, 2011
Last verified: January 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to understand the relevance of tissue oximetry measures of tissue flaps during surgery and during recovery, and to determine if T-Stat is a reliable and early method of detecting compromised flaps.
| Condition |
|---|
|
Ischemia |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Skin Flap Visible Light Spectroscopy (VLS) Oximetry for Monitoring Free-Flap Ischemia During Breast Reconstruction and Recovery |
Resource links provided by NLM:
Further study details as provided by Spectros Corporation:
Primary Outcome Measures:
- Flap Failure and Compromise by Tissue Saturation Values (Efficacy) [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Oximetric Diagnosis compared to Clinical Diagnosis, Doppler [ Time Frame: 72 hours ] [ Designated as safety issue: No ]
- Device Safety Measures (safety) [ Time Frame: 72 hours ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 50 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | December 2010 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
The tissue saturation of free flaps will be measured before, during, and after surgery and during recovery.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients undergoing surgical breast reconstruction.
Criteria
Inclusion Criteria:
- Under surgical breast reconstruction
- Informed consent
Exclusion Criteria:
- Failure to give consent
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01173133
Contacts
| Contact: John Griffin, MD | 650-348-1503 |
Locations
| United States, California | |
| Mills Penisula Hospital | Recruiting |
| Burlingame, California, United States, 94010-3282 | |
| Contact: John Griffin, MD 650-348-1503 | |
| Principal Investigator: John Griffin, MD | |
Sponsors and Collaborators
Spectros Corporation
Mills-Peninsula Medical Center
Stanford University
More Information
No publications provided
| Responsible Party: | Clinical Coordinator, Spectros Corporation |
| ClinicalTrials.gov Identifier: | NCT01173133 History of Changes |
| Other Study ID Numbers: | FLA-001 |
| Study First Received: | July 28, 2010 |
| Last Updated: | January 30, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Spectros Corporation:
|
Free Flap Surgery Ischemia |
Outcome Reconstructive Plastic Surgery Monitoring |
Additional relevant MeSH terms:
|
Ischemia Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013